Traynor Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Traynor Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-400	Closed	-$309K	–	377
2025 Q4	$309K	Buy	+400	New	+$272K	0.02%	248

Other funds holding REGN

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

MCI

McDonald Capital Investors Orinda, California $1.37B AUM 1.88% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Retirement Systems of Alabama Montgomery, Alabama $33.2B AUM 38.15% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Parnassus Investments San Francisco, California $37.4B AUM 35.42% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Traynor Capital Management's REGN Position: Q2 2026 in Review

Traynor Capital Management reduced its Regeneron Pharmaceuticals (REGN) stake by 90% in Q2 2026, selling an estimated $19.4M and leaving 3,005 shares worth $1.87M. The position accounts for 0.09% of the portfolio, ranked #97.

Traynor Capital Management first reported a position in REGN in Q4 2014 and has held it in 47 quarters since. The position peaked at $24.2M in Q4 2025. 481 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Traynor Capital Management held 3,005 shares of Regeneron Pharmaceuticals worth $1.87M as of Q2 2026.
Traynor Capital Management sold 28,461 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $19.4M.
Regeneron Pharmaceuticals made up 0.09% of Traynor Capital Management's portfolio in Q2 2026, its #97 holding.
Traynor Capital Management first reported a position in Regeneron Pharmaceuticals in Q4 2014 and has held it in 47 quarters since.
Traynor Capital Management's Regeneron Pharmaceuticals position peaked at $24.2M in Q4 2025.
481 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Traynor Capital Management's 13F filing for Q2 2026, filed 22 Jul 2026.